Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Abnormal bleeding tendency (abnormal bleeding), Macrothrombocytopenia, Megakaryocyte dysplasia, and Giant platelets and others; and common findings: Enlarged liver (hepatomegaly), Cataract, Low red blood cell count (anemia), and Decreased total lymphocyte count and others. 25 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 9 |
GALE encodes UDP-galactose-4-epimerase (348 aa). Catalyzes two distinct but analogous reactions: the reversible epimerization of UDP-glucose to UDP-galactose and the reversible epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. Highest expression in Minor Salivary Gland (40.9 TPM) and Esophagus Mucosa (39.8 TPM).
Thrombocytopenia 13, syndromic is associated with mutations in the GALE gene on chromosome 1.
The GALE protein participates in GALE V94M:GALE V94M:NAD+:NAD+, Defective GALE causes EDG, and DDX58/IFIH1-mediated induction of interferon-alpha/beta pathways.
GALE is classified as a druggable target (Druggable Genome and Enzyme categories) with score 0.0.
Epimerase deficiency galactosemia (GALE deficiency galactosemia) is a continuum comprising three forms:
Generalized. Enzyme activity is profoundly decreased in all tissues tested.
Peripheral. Enzyme activity is deficient in red blood cells (RBC) and circulating white blood cells, but normal or near normal in all other tissues.
Intermediate. Enzyme activity is deficient in RBC and circulating white blood cells and less than 50% of normal levels in other cells tested.
No approved treatments are currently available for thrombocytopenia 13, syndromic. The disease remains an area of unmet medical need.
When epimerase deficiency galactosemia is suspected during the diagnostic evaluation (for example, if total galactose is elevated on newborn screening results), initiation of a galactose/lactose-restricted diet should begin immediately . To the authors' knowledge, no clinical practice guidelines for epimerase deficiency galactosemia have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with epimerase deficiency galactosemia that is not clearly peripheral, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with Epimerase Deficiency Galactosemia
Table 5. Recommended Surveillance for Individuals with Generalized or Intermediate Epimerase Deficiency Galactosemia
System/Concern |
|---|
No clinical trials have been registered for thrombocytopenia 13, syndromic.
203 publications have been identified in PubMed for thrombocytopenia 13, syndromic. Research spans Epidemiology / Natural History (32%), Clinical Trial Publication (27%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 55 | 32% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 11:13 AM UTC
Online Mendelian Inheritance in Man
Brain and nerves | 2 | Intellectual disability, Cerebral hemorrhage |
Lab test results | 1 | Antinuclear antibody positivity |
Digestive system | 1 | Enlarged liver (hepatomegaly) |
Eyes | 1 | Cataract |
Bones and joints | 1 | Bone marrow hypocellularity |
Heart and blood vessels | 1 | Mitral valve prolapse |
The clinical severity of epimerase deficiency galactosemia caused by reduced activity of the enzyme GALE ranges from potentially lethal [, , , ] to apparently benign . Epimerase deficiency galactosemia can be divided by apparent enzyme activity level in specific cell types into the following three forms: generalized, peripheral, and intermediate . Note: In all three forms, GALE enzyme activity is deficient in peripheral circulating red and white blood cells. A key difference between generalized epimerase deficiency galactosemia and intermediate or peripheral epimerase deficiency galactosemia is that individuals with generalized epimerase deficiency galactosemia develop clinical findings on a normal milk diet, while infants with peripheral or intermediate epimerase deficiency galactosemia remain clinically well, at least in the neonatal period. Generalized Epimerase Deficiency Galactosemia Generalized epimerase deficiency galactosemia is rare, with only nine individuals from five families described in the literature [, , , , , , ]. summarizes the key clinical features of individuals reported with this phenotype. Table 2. Generalized Epimerase Deficiency Galactosemia: Frequency of Select Features
Feature | # of Personsw/Feature1 | Comment |
|---|---|---|
Hepatic abnormalities | 8/9 | May be ameliorated by treatment2 |
Short stature | 7/7 | In those who survive the neonatal period |
Developmental delay | 6/6 | Incl both children who experienced acute illness before diagnosis younger sibs who were switched to a low-galactose diet before onset of severe neonatal symptoms |
Hypotonia | 6/8 | May be ameliorated by treatment2 |
Sensorineural hearing loss | 4/7 | — |
Micrognathia | 4/6 | — |
Flexion deformities of the fingers | 3/6 | — |
Hip dysplasia | 3/7 | — |
Cataracts | 3/8 | May be ameliorated by treatment2 Renal dysfunction/tubulopathy |
Source: GeneReviews — "Epimerase Deficiency Galactosemia"
Because the numbers of individuals reported with molecularly confirmed epimerase deficiency galactosemia are currently limited, it is difficult to make strong genotype-phenotype correlations. However, some GALE variants have been associated with mild or severe outcomes in multiple affected individuals.
Individuals who are homozygous for (p.Val94Met) are likely to have generalized epimerase deficiency galactosemia and have a more severe outcome .
Individuals who have biallelic GALE alleles that are each associated with higher residual GALE activity in non-peripheral cells, such as (p.Lys257Arg) and (p.Gly319Glu), are more likely to have asymptomatic peripheral epimerase deficiency . However, too few individuals have been described to confirm or refute this prediction.
Source: GeneReviews — "Epimerase Deficiency Galactosemia"
Epimerase deficiency galactosemia should be suspected in individuals with the following newborn screening results, suggestive clinical features, and supportive laboratory findings while on a normal milk diet.
Newborn screening results
Source: GeneReviews — "Epimerase Deficiency Galactosemia"
GALT deficiency. Galactosemia caused by deficiency of the enzyme galactose-1-phosphate uridylyltransferase (GALT) may be divided into three clinical/biochemical phenotypes: (1) classic galactosemia; (2) clinical variant galactosemia; and (3) Duarte (biochemical variant) galactosemia. This categorization is based on: residual erythrocyte GALT enzyme activity; the levels of galactose metabolites (e.g., erythrocyte galactose-1-phosphate and urine galactitol) that are observed both off and on a lactose-restricted diet; and, most importantly, the likelihood that the affected individual will develop acute and chronic long-term complications. Biallelic pathogenic variants in GALT are causative; inheritance is autosomal recessive.
Source: GeneReviews — "Epimerase Deficiency Galactosemia"
Genetic testing for GALE is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for thrombocytopenia 13, syndromic has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measurement of height, weight, head circumference | — |
Neurologic | Neurologic eval | To incl assessment of tone |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech/language eval; Eval for early intervention/ special education |
Musculoskeletal | Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills; Contractures clubfoot; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Feeding/Nutrition | Nutrition/ feeding team eval | To incl eval of nutritional status feeding skills |
Hepatic | Liver function tests1 | — |
Renal | Urinalysis2 | Incl for non-glucose reducing substances; Consider renal imaging, such as renal ultrasound, if renal abnormalities are suspected. |
Eyes | Ophthalmologic eval | To assess for cataracts |
Hearing | Audiologic eval | Assess for sensorineural hearing loss. Genetic |
counseling | By genetics professionals3 | To inform affected persons their families re nature, MOI, implications of epimerase deficiency galactosemia in order to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Generalized or Intermediate Epimerase Deficiency Galactosemia Principle/Manifestation/Concern | Treatment | Considerations/Other Galactose/lactose- |
restricted diet1 | In infants: switch from breast milk or a milk-based formula to a formula w/trace levels of galactose or lactose (e.g., soy formula). | Elemental formula (which is prescribed for infants w/classic galactosemia) should NOT be used.2 In older children: Dietary restriction involves continued restriction of dairy products. |
delay | See . | Contractures |
clubfoot | Standard treatment per orthopedist | Poor weight gain/ |
Failure to thrive | Feeding therapy | — |
Cataracts | Mature cataracts that do not resolve w/dietary restriction of galactose/lactose may require surgical removal. | — |
Hearing loss | Hearing aids may be helpful; per otolaryngologist. | Community hearing services through early intervention or school district Family/ |
Community | Ensure appropriate social work involvement to connect families w/local resources support. | Consider involvement in adaptive sports or Special Olympics. 1. |
Source: GeneReviews — "Epimerase Deficiency Galactosemia"
Persons with generalized epimerase deficiency galactosemia should be on a galactose/lactose-restricted diet, certainly as infants and perhaps for life. Persons with intermediate epimerase deficiency galactosemia may be placed on a galactose/lactose-restricted diet, either transiently or long term. Assessment of hemolysate gal-1P and/or urinary galactitol following a galactose challenge (e.g., 2 weeks on a normal diet) may help determine if an individual should remain on a galactose/lactose-restricted diet for longer periods of time.
Source: GeneReviews — "Epimerase Deficiency Galactosemia"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Epimerase Deficiency Galactosemia"
View trials for thrombocytopenia 13, syndromic
Evaluation
Frequency |
|---|
Constitutional | Measurement of growth parameters | At each visit |
Biochemical | Assessment of hemolysate gal-1P or urinary galactitol1,2 | At each visit or as indicated by any ongoing concerns or relevant dietary changes |
Development | Monitor developmental progress educational needs. | At each visit Musculoskeletal |
Eyes | Ophthalmology eval | As clinically indicated (assuming the affected person is on a galactose-restricted diet) |
Hearing | Audiology eval | At least annually in infancy childhood or as clinically indicated Family/ |
Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources) care coordination. | At each visit OT = occupational therapy; PT = physical therapy 1. Especially if the diet is to be normalized Acceptable levels of gal-1P in GALE deficiency are not known but are estimated from experience with classic galactosemia to be 3.5 mg/100 mL in red blood cells. |
Source: GeneReviews — "Epimerase Deficiency Galactosemia"
Phenotype severity distribution: 8 always present features, 12 common features.
Clinical study results
46 |
27% |
Research summaries | 30 | 17% |
Patient case studies | 16 | 9% |
Testing and diagnosis research | 11 | 6% |
Laboratory research | 10 | 6% |
New treatment approaches | 3 | 2% |
Other research | 1 | 1% |
Zhao J (2026). [PMID: 40685857](https://pubmed.ncbi.nlm.nih.gov/40685857/). *J Biomed Res*. [Basic Science / Preclinical]
Ortiz-Maldonado V (2026). [PMID: 41651004](https://pubmed.ncbi.nlm.nih.gov/41651004/). *Lancet Haematol*. [Clinical Trial Publication]
Panizo-Inogés M (2026). [PMID: 41915216](https://pubmed.ncbi.nlm.nih.gov/41915216/). *Cancer Immunol Immunother*. [Epidemiology / Natural History]
Erdogan Yucel E (2026). [PMID: 42195121](https://pubmed.ncbi.nlm.nih.gov/42195121/). *Medicina (Kaunas)*. [Review / Meta-Analysis]
Chandrakasan S (2026). [PMID: 41419161](https://pubmed.ncbi.nlm.nih.gov/41419161/). *Clin Immunol*. [Epidemiology / Natural History]
Öztürk AG (2026). [PMID: 41437329](https://pubmed.ncbi.nlm.nih.gov/41437329/). *Turk J Haematol*. [Clinical Trial Publication]
Belge Bilgin G (2026). [PMID: 41290367](https://pubmed.ncbi.nlm.nih.gov/41290367/). *J Nucl Med*. [Clinical Trial Publication]
Kebede SS (2026). [PMID: 41960798](https://pubmed.ncbi.nlm.nih.gov/41960798/). *Biomed Res Int*. [Epidemiology / Natural History]
van den Hoek L (2026). [PMID: 41785896](https://pubmed.ncbi.nlm.nih.gov/41785896/). *Lancet Oncol*. [Clinical Trial Publication]
Nuñez Zuno JA (2026). [PMID: 29261870](https://pubmed.ncbi.nlm.nih.gov/29261870/). *Unknown Journal*. [Case Report / Case Series]